Avalyn Pharma (AVLN) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $57.00 from $53.00 | Aug 13, 2026 |
| Guggenheim | Initiated Coverage | Buy | $80.00 | May 26, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | $51.00 | May 26, 2026 |
| Morgan Stanley | Initiated Coverage | Overweight | $53.00 | May 26, 2026 |
Frequently asked questions
Is AVLN a buy, sell, or hold?
Analysts covering Avalyn Pharma currently average a Buy rating: 4 buy, 0 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on AVLN?
On Aug 13, 2026, Morgan Stanley maintained Avalyn Pharma at Overweight with a price target of $57.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.